

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	11	10.6	103.5	(51.6-185.2)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	10.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.7	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	24	38.8	61.9	(39.6-92.1)
Female	0	0.3	nc	(nc-nc)	Female	34	34.5	98.5	(68.2-137.7)
<u>Lung and Bronchus</u>									
Male	5	5.5	90.7	(29.2-211.8)					
Female	3	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	40.7	61.4	(39.8-90.7)	Male	28	25.1	111.5	(74.1-161.2)
Female	5	15.6	32.1	(10.3-74.9)	Female	22	19.5	112.9	(70.7-170.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.3	82.0	(30.0-178.6)	Male	11	8.2	133.6	(66.6-239.1)
Female	4	6.3	nc	(nc-nc)	Female	8	7.0	114.8	(49.4-226.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.4	nc	(nc-nc)	Male	18	22.5	79.9	(47.3-126.3)
Female	175	162.0	108.0	(92.6-125.3)	Female	24	21.1	113.7	(72.9-169.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.9	nc	(nc-nc)	Male	17	18.6	91.2	(53.1-146.0)
<u>Colon / Rectum</u>					Female	7	8.8	79.5	(31.8-163.8)
Male	38	43.1	88.2	(62.4-121.1)	<u>Ovary</u>				
Female	32	45.3	70.6	(48.3-99.7)	Female	15	14.0	107.3	(60.0-176.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	10.3	nc	(nc-nc)	Male	10	14.4	69.6	(33.3-128.1)
Female	0	3.0	nc	(nc-nc)	Female	17	15.9	106.8	(62.2-171.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.4	nc	(nc-nc)	Male	131	124.0	105.6	(88.3-125.3)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	9.7	nc	(nc-nc)
Male	17	21.9	77.8	(45.3-124.6)	Female	6	6.2	97.3	(35.5-211.9)
Female	4	13.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.8	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.8	nc	(nc-nc)	Male	8	9.3	86.0	(37.0-169.4)
<u>Leukemia</u>					Female	36	26.3	136.9	(95.9-189.5)
Male	14	16.0	87.2	(47.7-146.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	12.1	99.2	(51.2-173.3)	Female	29	36.0	80.7	(54.0-115.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	13.8	nc	(nc-nc)	Male	405	512.1	79.1	(71.6-87.2)
Female	5	5.0	100.9	(32.5-235.5)	Female	490	552.5	88.7	(81.0-96.9)
<u>Lung and Bronchus</u>									
Male	28	71.8	39.0	(25.9-56.4)					
Female	45	80.2	56.1	(40.9-75.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	11.8	84.7	(40.5-155.7)
Female	0	0.1	nc	(nc-nc)	Female	13	11.9	109.0	(58.0-186.5)
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	9.4	nc	(nc-nc)	Male	7	5.5	127.7	(51.2-263.1)
Female	8	2.6	306.1	(131.8-603.2)	Female	8	3.6	222.5	(95.8-438.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.6	318.9	(102.8-744.3)	Male	3	1.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	47	29.1	161.8	(118.9-215.1)	Female	4	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	3.7	136.7	(44.0-319.0)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	7	9.5	73.5	(29.5-151.5)	<u>Ovary</u>				
Female	5	7.8	64.3	(20.7-150.2)	Female	4	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	5	3.2	157.8	(50.8-368.2)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	43	23.5	183.2	(132.6-246.8)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.2	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.3	nc	(nc-nc)
Male	6	3.6	165.7	(60.5-360.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	2.3	309.0	(123.8-636.7)	Female	11	6.5	168.3	(83.9-301.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.8	nc	(nc-nc)	Male	121	108.4	111.6	(92.6-133.3)
Female	1	0.9	nc	(nc-nc)	Female	126	98.0	128.5	(107.1-153.0)
<u>Lung and Bronchus</u>									
Male	7	15.6	44.7	(17.9-92.2)					
Female	9	13.5	66.6	(30.4-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	8.0	174.0	(95.0-291.9)	Male	6	5.7	104.7	(38.2-227.8)
Female	1	3.6	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	5.1	195.4	(93.5-359.3)
Female	42	42.4	99.0	(71.3-133.8)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	4.6	130.2	(47.5-283.4)
<u>Colon / Rectum</u>					Female	0	2.2	nc	(nc-nc)
Male	5	9.6	52.3	(16.9-122.2)	<u>Ovary</u>				
Female	7	10.8	64.8	(26.0-133.5)	Female	6	3.6	165.0	(60.3-359.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.3	nc	(nc-nc)	Male	6	3.1	192.1	(70.1-418.1)
Female	0	0.7	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	33	28.7	114.9	(79.1-161.4)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.7	117.5	(53.6-223.1)
Male	3	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.0	nc	(nc-nc)	Female	14	9.5	148.0	(80.8-248.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.3	nc	(nc-nc)	Male	130	115.3	112.8	(94.2-133.9)
Female	2	1.2	nc	(nc-nc)	Female	122	139.8	87.3	(72.5-104.2)
<u>Lung and Bronchus</u>									
Male	20	15.1	132.8	(81.1-205.0)					
Female	14	19.4	72.2	(39.5-121.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	22.3	67.1	(37.5-110.7)	Male	18	13.2	136.9	(81.1-216.3)
Female	7	8.2	85.6	(34.3-176.3)	Female	14	10.0	140.6	(76.8-236.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.6	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	11.9	84.3	(40.3-155.0)
Female	86	80.2	107.2	(85.8-132.4)	Female	12	10.9	110.6	(57.1-193.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.4	nc	(nc-nc)	Male	5	9.4	53.3	(17.2-124.4)
<u>Colon / Rectum</u>					Female	0	4.5	nc	(nc-nc)
Male	11	23.2	47.5	(23.7-85.0)	<u>Ovary</u>				
Female	15	24.3	61.7	(34.5-101.7)	Female	5	7.1	70.6	(22.7-164.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.3	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	4	8.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	54	63.1	85.6	(64.3-111.7)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.2	96.1	(31.0-224.3)
Male	11	11.0	99.9	(49.8-178.9)	Female	2	3.3	nc	(nc-nc)
Female	3	6.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.8	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.5	111.5	(35.9-260.2)
<u>Leukemia</u>					Female	9	12.9	69.9	(31.9-132.8)
Male	15	8.4	178.3	(99.7-294.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.4	nc	(nc-nc)	Female	12	17.7	67.8	(35.0-118.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	7.0	nc	(nc-nc)	Male	213	267.6	79.6	(69.3-91.0)
Female	6	2.5	238.0	(86.9-518.0)	Female	234	281.3	83.2	(72.9-94.6)
<u>Lung and Bronchus</u>									
Male	24	38.2	62.9	(40.3-93.6)					
Female	24	40.5	59.3	(38.0-88.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	75	81.8	91.7	(72.1-114.9)	Male	32	56.9	56.2	(38.5-79.4)
Female	37	31.9	115.9	(81.6-159.7)	Female	26	49.1	53.0	(34.6-77.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	19.8	75.9	(42.5-125.2)	Male	17	17.5	97.1	(56.5-155.4)
Female	14	16.1	87.0	(47.5-146.0)	Female	23	14.7	156.5	(99.2-234.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.0	nc	(nc-nc)	Male	44	51.3	85.8	(62.3-115.2)
Female	307	371.9	82.5	(73.6-92.3)	Female	36	46.5	77.4	(54.2-107.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	14.0	121.2	(70.6-194.1)	Male	58	44.1	131.5	(99.9-170.0)
<u>Colon / Rectum</u>					Female	13	19.6	66.4	(35.3-113.5)
Male	87	94.7	91.9	(73.6-113.4)	<u>Ovary</u>				
Female	101	96.5	104.7	(85.3-127.2)	Female	25	32.3	77.4	(50.1-114.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	22	22.2	99.0	(62.0-150.0)	Male	29	30.5	95.2	(63.8-136.8)
Female	4	6.2	nc	(nc-nc)	Female	28	32.5	86.2	(57.2-124.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	14	9.3	149.8	(81.8-251.4)	Male	214	277.2	77.2	(67.2-88.3)
Female	4	7.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	25	20.6	121.2	(78.4-178.9)
Male	59	51.1	115.6	(88.0-149.1)	Female	32	13.1	244.5	(167.2-345.2)
Female	34	29.4	115.7	(80.1-161.7)	<u>Testis</u>				
<u>Larynx</u>					Male	14	18.6	75.4	(41.2-126.6)
Male	16	13.1	122.2	(69.8-198.5)	<u>Thyroid</u>				
Female	6	4.0	151.1	(55.2-329.0)	Male	17	26.2	64.9	(37.8-104.0)
<u>Leukemia</u>					Female	79	80.0	98.7	(78.1-123.0)
Male	35	37.3	94.0	(65.4-130.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	35	28.4	123.4	(85.9-171.6)	Female	81	81.2	99.7	(79.2-124.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	65	31.6	205.9	(158.9-262.4)	Male	1135	1145.1	99.1	(93.4-105.1)
Female	7	10.7	65.5	(26.2-135.0)	Female	1200	1252.9	95.8	(90.4-101.4)
<u>Lung and Bronchus</u>									
Male	178	147.7	120.5	(103.4-139.6)					
Female	191	166.5	114.7	(99.0-132.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	25.4	110.2	(73.2-159.3)	Male	12	16.3	73.7	(38.0-128.7)
Female	4	10.2	nc	(nc-nc)	Female	15	13.1	114.1	(63.8-188.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.8	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	5	4.6	108.4	(34.9-253.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	14	14.5	96.7	(52.8-162.2)
Female	88	108.1	81.4	(65.3-100.3)	Female	13	14.0	92.8	(49.4-158.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	3.3	209.7	(84.0-432.1)	Male	7	12.5	56.0	(22.4-115.5)
<u>Colon / Rectum</u>					Female	4	5.9	nc	(nc-nc)
Male	29	27.6	104.9	(70.3-150.7)	<u>Ovary</u>				
Female	27	29.5	91.5	(60.3-133.1)	Female	9	9.3	96.5	(44.0-183.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	6.7	nc	(nc-nc)	Male	8	9.2	87.3	(37.6-172.0)
Female	2	2.0	nc	(nc-nc)	Female	12	10.4	114.9	(59.3-200.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	67	83.1	80.6	(62.5-102.4)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	6.2	129.8	(55.9-255.8)
Male	23	14.4	159.5	(101.1-239.4)	Female	4	4.0	nc	(nc-nc)
Female	5	8.7	57.6	(18.6-134.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.1	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	18.0	33.3	(12.2-72.4)
Male	7	10.1	69.1	(27.7-142.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	8.0	75.3	(27.5-163.8)	Female	22	24.4	90.3	(56.6-136.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	9.3	75.6	(30.3-155.8)	Male	292	333.2	87.6	(77.9-98.3)
Female	2	3.3	nc	(nc-nc)	Female	299	367.4	81.4	(72.4-91.1)
<u>Lung and Bronchus</u>									
Male	32	45.6	70.2	(48.0-99.1)					
Female	34	53.2	63.9	(44.2-89.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.7	70.8	(32.3-134.3)	Male	8	8.0	99.6	(42.9-196.3)
Female	6	4.2	142.3	(52.0-309.8)	Female	3	6.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.4	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.3	69.0	(22.2-160.9)
Female	55	50.8	108.2	(81.5-140.8)	Female	6	6.2	97.5	(35.6-212.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	9	6.1	147.0	(67.1-279.2)
<u>Colon / Rectum</u>					Female	0	2.7	nc	(nc-nc)
Male	14	14.0	99.7	(54.5-167.3)	<u>Ovary</u>				
Female	14	12.5	112.1	(61.2-188.1)	Female	3	4.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.9	nc	(nc-nc)	Male	42	40.1	104.8	(75.5-141.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	7	7.2	97.7	(39.1-201.3)	Female	1	1.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.5	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	10	9.0	110.6	(52.9-203.4)
Male	8	5.1	157.9	(68.0-311.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.4	nc	(nc-nc)	Female	15	11.9	126.2	(70.6-208.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.4	nc	(nc-nc)	Male	168	164.2	102.3	(87.4-119.0)
Female	3	1.5	nc	(nc-nc)	Female	156	165.8	94.1	(79.9-110.1)
<u>Lung and Bronchus</u>									
Male	24	22.4	107.0	(68.6-159.3)					
Female	16	22.7	70.5	(40.3-114.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	71.3	101.0	(79.1-127.3)	Male	43	48.4	88.8	(64.3-119.6)
Female	25	28.7	87.1	(56.4-128.7)	Female	31	42.7	72.6	(49.3-103.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	16.5	115.4	(69.4-180.2)	Male	32	15.2	211.1	(144.4-298.0)
Female	17	14.2	119.4	(69.5-191.2)	Female	16	13.1	121.7	(69.5-197.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.6	194.2	(62.6-453.2)	Male	51	43.8	116.4	(86.7-153.1)
Female	325	328.7	98.9	(88.4-110.2)	Female	51	41.2	123.8	(92.2-162.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	12.0	133.8	(76.4-217.2)	Male	50	36.8	135.9	(100.8-179.1)
<u>Colon / Rectum</u>					Female	19	17.4	109.2	(65.7-170.6)
Male	120	81.8	146.8	(121.7-175.5)	<u>Ovary</u>				
Female	111	85.6	129.6	(106.6-156.1)	Female	24	28.6	84.0	(53.8-125.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	18.9	111.0	(68.7-169.7)	Male	27	26.1	103.6	(68.3-150.8)
Female	5	5.6	89.4	(28.8-208.6)	Female	24	29.2	82.2	(52.7-122.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	7.4	67.4	(21.7-157.2)	Male	290	232.0	125.0	(111.0-140.2)
Female	2	6.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	21	17.8	118.1	(73.1-180.5)
Male	35	43.1	81.2	(56.5-112.9)	Female	22	11.6	189.9	(118.9-287.5)
Female	28	26.2	106.9	(71.0-154.6)	<u>Testis</u>				
<u>Larynx</u>					Male	14	14.6	96.1	(52.5-161.3)
Male	15	11.1	134.8	(75.4-222.4)	<u>Thyroid</u>				
Female	4	3.6	nc	(nc-nc)	Male	20	21.7	92.2	(56.3-142.4)
<u>Leukemia</u>					Female	53	68.3	77.6	(58.2-101.6)
Male	46	31.6	145.6	(106.6-194.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	32	25.3	126.6	(86.6-178.7)	Female	73	72.3	101.0	(79.2-127.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	57	26.3	216.5	(164.0-280.6)	Male	1230	972.1	126.5	(119.6-133.8)
Female	18	9.5	188.7	(111.8-298.2)	Female	1176	1110.3	105.9	(99.9-112.1)
<u>Lung and Bronchus</u>									
Male	195	127.2	153.3	(132.5-176.4)					
Female	171	150.5	113.7	(97.3-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.7	76.2	(39.3-133.1)	Male	24	9.9	242.3	(155.2-360.5)
Female	10	5.4	184.8	(88.5-339.8)	Female	13	7.1	184.4	(98.1-315.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.8	nc	(nc-nc)	Male	5	3.2	154.8	(49.9-361.4)
Female	4	2.3	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.8	158.9	(86.8-266.6)
Female	60	58.7	102.2	(78.0-131.6)	Female	13	7.4	175.1	(93.2-299.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	5	7.5	67.0	(21.6-156.3)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	13	17.0	76.6	(40.7-130.9)	<u>Ovary</u>				
Female	21	15.7	133.8	(82.8-204.6)	Female	8	5.0	158.6	(68.3-312.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.1	nc	(nc-nc)	Male	5	5.6	89.4	(28.8-208.5)
Female	0	1.1	nc	(nc-nc)	Female	7	5.5	127.3	(51.0-262.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	44	49.7	88.6	(64.4-118.9)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.8	nc	(nc-nc)
Male	7	8.7	80.6	(32.3-166.0)	Female	3	2.1	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.6	373.7	(136.4-813.3)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.8	159.3	(58.2-346.7)
<u>Leukemia</u>					Female	18	9.9	181.4	(107.5-286.8)
Male	11	6.1	179.5	(89.5-321.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.2	nc	(nc-nc)	Female	17	13.1	129.8	(75.6-207.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	5.5	nc	(nc-nc)	Male	190	202.0	94.1	(81.2-108.4)
Female	1	1.8	nc	(nc-nc)	Female	233	197.4	118.0	(103.4-134.2)
<u>Lung and Bronchus</u>									
Male	19	28.2	67.3	(40.5-105.1)					
Female	29	28.4	102.0	(68.3-146.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	46.7	57.8	(38.1-84.1)	Male	10	32.5	30.7	(14.7-56.5)
Female	21	18.9	111.4	(68.9-170.3)	Female	16	29.4	54.3	(31.0-88.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	10.9	46.1	(14.8-107.5)	Male	7	10.1	69.1	(27.7-142.4)
Female	7	9.3	75.0	(30.0-154.5)	Female	5	8.7	57.3	(18.4-133.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	43	29.2	147.2	(106.5-198.3)
Female	185	223.3	82.9	(71.3-95.7)	Female	26	27.6	94.3	(61.6-138.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	8.7	172.8	(96.7-285.1)	Male	23	24.7	93.2	(59.1-139.9)
<u>Colon / Rectum</u>					Female	11	11.6	94.7	(47.2-169.4)
Male	71	53.4	132.9	(103.8-167.6)	<u>Ovary</u>				
Female	72	57.6	125.0	(97.8-157.5)	Female	16	19.2	83.4	(47.6-135.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	12.6	134.9	(78.6-216.1)	Male	20	17.2	116.2	(70.9-179.4)
Female	8	3.6	219.8	(94.6-433.1)	Female	18	19.3	93.3	(55.3-147.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	5.3	nc	(nc-nc)	Male	128	152.3	84.0	(70.1-99.9)
Female	4	4.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	11.7	136.3	(77.9-221.4)
Male	36	28.9	124.8	(87.4-172.7)	Female	7	7.8	89.7	(35.9-184.9)
Female	21	17.4	120.9	(74.8-184.8)	<u>Testis</u>				
<u>Larynx</u>					Male	7	10.8	65.0	(26.0-133.9)
Male	9	7.4	121.4	(55.4-230.5)	<u>Thyroid</u>				
Female	2	2.3	nc	(nc-nc)	Male	15	15.1	99.4	(55.6-163.9)
<u>Leukemia</u>					Female	59	49.1	120.3	(91.5-155.1)
Male	22	20.7	106.1	(66.5-160.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	16.6	96.5	(55.1-156.6)	Female	50	48.0	104.2	(77.3-137.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	17.7	141.5	(91.6-208.9)	Male	639	644.5	99.1	(91.6-107.1)
Female	16	6.3	255.2	(145.8-414.5)	Female	740	746.7	99.1	(92.1-106.5)
<u>Lung and Bronchus</u>									
Male	116	83.9	138.3	(114.3-165.9)					
Female	108	97.9	110.3	(90.5-133.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	8.1	nc	(nc-nc)	Male	9	4.7	191.1	(87.2-362.7)
Female	1	2.7	nc	(nc-nc)	Female	5	3.4	146.6	(47.2-342.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	8	4.2	188.5	(81.2-371.4)
Female	29	29.3	99.0	(66.3-142.2)	Female	2	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.6	nc	(nc-nc)
Male	2	8.3	nc	(nc-nc)	<u>Ovary</u>				
Female	6	7.6	79.4	(29.0-172.7)	Female	1	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.0	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	23.3	102.9	(65.9-153.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.9	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	8	4.6	174.3	(75.1-343.5)
Male	1	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	6	6.7	89.1	(32.5-193.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.6	nc	(nc-nc)	Male	84	97.0	86.6	(69.1-107.2)
Female	0	0.9	nc	(nc-nc)	Female	86	97.8	87.9	(70.3-108.6)
<u>Lung and Bronchus</u>									
Male	8	13.7	58.3	(25.1-114.9)					
Female	8	14.6	55.0	(23.7-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	16.7	143.3	(91.8-213.2)	Male	25	12.2	205.5	(132.9-303.3)
Female	0	5.8	nc	(nc-nc)	Female	21	10.3	203.9	(126.2-311.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.2	189.3	(81.5-373.0)	Male	5	3.8	131.9	(42.5-307.8)
Female	6	3.4	178.9	(65.3-389.3)	Female	1	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	13	11.0	118.4	(63.0-202.5)
Female	93	83.6	111.3	(89.8-136.3)	Female	3	9.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.2	nc	(nc-nc)	Male	10	9.9	101.0	(48.4-185.8)
<u>Colon / Rectum</u>					Female	1	4.0	nc	(nc-nc)
Male	25	20.6	121.3	(78.4-179.0)	<u>Ovary</u>				
Female	27	19.0	142.4	(93.8-207.1)	Female	8	7.0	114.7	(49.4-226.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.8	nc	(nc-nc)	Male	5	6.4	77.8	(25.1-181.5)
Female	1	1.2	nc	(nc-nc)	Female	6	5.9	101.3	(37.0-220.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	60	59.3	101.1	(77.2-130.2)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	114.7	(37.0-267.8)
Male	13	11.4	114.5	(60.9-195.8)	Female	4	2.5	nc	(nc-nc)
Female	5	6.2	81.2	(26.2-189.4)	<u>Testis</u>				
<u>Larynx</u>					Male	8	3.5	231.6	(99.7-456.4)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	15	5.9	254.9	(142.6-420.5)
<u>Leukemia</u>					Female	17	18.1	93.7	(54.6-150.0)
Male	6	7.8	76.6	(28.0-166.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	5.4	202.7	(101.0-362.6)	Female	11	18.0	61.2	(30.5-109.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	6.9	131.0	(59.8-248.7)	Male	284	243.5	116.6	(103.4-131.0)
Female	3	2.1	nc	(nc-nc)	Female	282	260.5	108.2	(96.0-121.6)
<u>Lung and Bronchus</u>									
Male	35	30.6	114.5	(79.7-159.2)					
Female	34	31.7	107.4	(74.4-150.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	27.4	83.8	(53.1-125.8)	Male	41	16.5	248.1	(178.0-336.6)
Female	10	9.7	103.2	(49.4-189.7)	Female	26	12.6	205.7	(134.3-301.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.7	nc	(nc-nc)	Male	8	5.5	146.7	(63.2-289.2)
Female	3	4.1	nc	(nc-nc)	Female	7	4.4	158.3	(63.4-326.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	14	14.9	94.1	(51.4-157.9)
Female	126	107.1	117.6	(98.0-140.0)	Female	13	13.4	97.3	(51.7-166.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.3	151.9	(49.0-354.6)	Male	11	11.9	92.1	(45.9-164.9)
<u>Colon / Rectum</u>					Female	7	5.7	123.3	(49.4-254.0)
Male	25	28.5	87.8	(56.8-129.6)	<u>Ovary</u>				
Female	23	28.1	81.9	(51.9-122.9)	Female	6	9.1	65.6	(23.9-142.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.8	132.6	(60.5-251.7)	Male	10	9.6	104.5	(50.0-192.2)
Female	2	1.9	nc	(nc-nc)	Female	13	9.9	131.9	(70.2-225.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	95	80.5	118.0	(95.5-144.3)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.5	92.9	(33.9-202.3)
Male	12	14.2	84.6	(43.7-147.8)	Female	1	3.8	nc	(nc-nc)
Female	6	8.5	70.4	(25.7-153.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.2	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	5.8	120.6	(48.3-248.4)
<u>Leukemia</u>					Female	14	17.7	79.2	(43.3-132.9)
Male	11	10.6	104.0	(51.9-186.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.6	105.9	(45.6-208.6)	Female	20	24.2	82.5	(50.4-127.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	8.9	nc	(nc-nc)	Male	339	336.8	100.7	(90.2-112.0)
Female	1	3.2	nc	(nc-nc)	Female	364	356.9	102.0	(91.8-113.0)
<u>Lung and Bronchus</u>									
Male	28	48.2	58.1	(38.6-83.9)					
Female	39	51.5	75.8	(53.9-103.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.5	66.6	(21.5-155.4)	Male	10	4.5	222.1	(106.3-408.5)
Female	4	2.8	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	4.1	269.8	(134.5-482.7)
Female	34	27.1	125.5	(86.9-175.4)	Female	3	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	9	7.7	117.4	(53.6-222.8)	<u>Ovary</u>				
Female	11	8.0	137.9	(68.7-246.7)	Female	0	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	24.9	56.3	(30.7-94.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.8	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.1	122.3	(39.4-285.5)
Male	8	2.8	281.2	(121.1-554.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	7	6.2	112.9	(45.2-232.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.5	nc	(nc-nc)	Male	84	95.2	88.3	(70.4-109.3)
Female	1	0.9	nc	(nc-nc)	Female	107	94.7	113.0	(92.6-136.6)
<u>Lung and Bronchus</u>									
Male	7	13.4	52.1	(20.9-107.3)					
Female	18	13.8	130.3	(77.2-205.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	39.5	86.0	(59.6-120.2)	Male	25	26.3	95.2	(61.6-140.5)
Female	11	13.4	81.8	(40.8-146.4)	Female	14	19.9	70.4	(38.5-118.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.2	73.2	(26.7-159.3)	Male	7	8.3	84.5	(33.8-174.1)
Female	10	6.3	157.6	(75.5-289.9)	Female	6	6.2	96.8	(35.4-210.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	18	23.4	76.9	(45.6-121.5)
Female	144	158.9	90.6	(76.4-106.7)	Female	23	19.4	118.6	(75.1-177.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.7	105.1	(38.4-228.9)	Male	20	19.6	101.9	(62.2-157.4)
<u>Colon / Rectum</u>					Female	19	8.2	232.2	(139.7-362.6)
Male	43	44.2	97.2	(70.3-130.9)	<u>Ovary</u>				
Female	50	39.8	125.7	(93.3-165.7)	Female	15	13.5	111.1	(62.2-183.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	10.3	116.6	(60.2-203.7)	Male	13	14.3	91.1	(48.5-155.9)
Female	6	2.6	227.7	(83.2-495.6)	Female	15	13.5	110.9	(62.0-182.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.4	207.3	(83.1-427.2)	Male	107	122.6	87.3	(71.5-105.4)
Female	3	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	9.7	51.3	(16.5-119.7)
Male	22	23.0	95.6	(59.9-144.7)	Female	5	5.4	93.1	(30.0-217.2)
Female	10	12.5	80.1	(38.4-147.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	6.5	nc	(nc-nc)
Male	7	6.0	115.8	(46.4-238.6)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	11	11.1	99.1	(49.4-177.4)
<u>Leukemia</u>					Female	44	31.7	139.0	(101.0-186.5)
Male	14	16.6	84.2	(46.0-141.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	11.3	123.6	(67.5-207.4)	Female	33	35.1	94.1	(64.8-132.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	14.2	91.2	(48.5-156.0)	Male	451	521.9	86.4	(78.6-94.8)
Female	8	4.5	177.0	(76.2-348.8)	Female	551	525.2	104.9	(96.3-114.0)
<u>Lung and Bronchus</u>									
Male	52	70.8	73.5	(54.9-96.4)					
Female	71	71.8	98.8	(77.2-124.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	27.4	69.3	(41.7-108.2)	Male	31	17.9	172.8	(117.4-245.2)
Female	10	9.0	110.8	(53.0-203.8)	Female	28	13.5	206.8	(137.4-298.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.5	180.2	(86.3-331.4)	Male	13	5.8	225.1	(119.7-384.9)
Female	5	4.4	113.7	(36.6-265.3)	Female	1	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	16.1	80.8	(43.0-138.1)
Female	142	114.7	123.8	(104.3-145.9)	Female	12	13.4	89.4	(46.2-156.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.8	159.4	(58.2-347.0)	Male	12	14.4	83.3	(43.0-145.4)
<u>Colon / Rectum</u>					Female	4	5.8	nc	(nc-nc)
Male	21	30.7	68.4	(42.3-104.6)	<u>Ovary</u>				
Female	26	26.4	98.5	(64.4-144.4)	Female	10	9.7	103.3	(49.4-189.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.5	106.4	(45.8-209.7)	Male	12	10.2	118.1	(61.0-206.4)
Female	0	1.9	nc	(nc-nc)	Female	12	9.1	132.0	(68.1-230.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	112	97.0	115.4	(95.0-138.9)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	6.8	nc	(nc-nc)
Male	20	16.5	121.2	(74.0-187.2)	Female	3	3.6	nc	(nc-nc)
Female	6	8.8	68.6	(25.0-149.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.4	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	9	7.3	123.0	(56.1-233.5)
<u>Leukemia</u>					Female	19	21.0	90.6	(54.5-141.5)
Male	15	11.4	131.8	(73.7-217.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	7.4	80.6	(29.4-175.4)	Female	21	26.7	78.7	(48.7-120.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	10.4	125.2	(66.6-214.2)	Male	390	374.1	104.2	(94.2-115.1)
Female	1	3.2	nc	(nc-nc)	Female	407	366.7	111.0	(100.5-122.3)
<u>Lung and Bronchus</u>									
Male	46	50.0	92.0	(67.3-122.7)					
Female	65	50.0	130.0	(100.3-165.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	23.0	130.3	(87.9-186.1)	Male	14	13.3	104.9	(57.3-176.1)
Female	7	9.0	77.7	(31.1-160.1)	Female	18	10.2	176.7	(104.7-279.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	5	4.4	112.6	(36.3-262.8)
Female	1	3.3	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	15	11.9	125.9	(70.4-207.6)
Female	88	86.6	101.6	(81.5-125.2)	Female	15	11.6	128.9	(72.1-212.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	15	9.2	162.3	(90.8-267.7)
<u>Colon / Rectum</u>					Female	5	4.8	104.3	(33.6-243.3)
Male	19	22.7	83.8	(50.4-130.8)	<u>Ovary</u>				
Female	21	24.3	86.3	(53.4-131.9)	Female	5	7.6	66.1	(21.3-154.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.6	89.7	(28.9-209.3)	Male	10	7.8	128.5	(61.5-236.3)
Female	0	1.7	nc	(nc-nc)	Female	9	9.0	100.5	(45.8-190.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	65	66.1	98.3	(75.9-125.4)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	5.3	nc	(nc-nc)
Male	11	11.2	98.5	(49.1-176.2)	Female	2	3.2	nc	(nc-nc)
Female	8	7.3	109.0	(46.9-214.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	1.1	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	10	12.3	81.0	(38.8-149.0)
Male	9	8.5	106.2	(48.5-201.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	6.5	154.1	(73.8-283.3)	Female	12	20.0	60.1	(31.0-104.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.0	85.3	(31.2-185.8)	Male	278	273.9	101.5	(89.9-114.2)
Female	0	2.8	nc	(nc-nc)	Female	287	302.3	94.9	(84.3-106.6)
<u>Lung and Bronchus</u>									
Male	39	40.6	96.0	(68.3-131.3)					
Female	48	48.5	99.0	(73.0-131.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.0	149.3	(77.0-260.8)	Male	7	5.1	138.5	(55.5-285.4)
Female	4	2.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	38	31.4	120.9	(85.6-166.0)	Female	5	3.8	131.1	(42.2-305.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	13	3.9	337.5	(179.5-577.1)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	12	8.3	144.6	(74.6-252.6)	<u>Ovary</u>				
Female	4	7.5	nc	(nc-nc)	Female	5	2.7	187.2	(60.3-436.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	42	27.5	152.9	(110.2-206.7)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.9	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.2	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.1	nc	(nc-nc)	Female	12	7.4	162.3	(83.7-283.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.8	nc	(nc-nc)	Male	139	105.6	131.7	(110.7-155.5)
Female	3	0.9	nc	(nc-nc)	Female	106	102.6	103.3	(84.6-125.0)
<u>Lung and Bronchus</u>									
Male	18	15.1	119.1	(70.5-188.2)					
Female	10	14.8	67.3	(32.2-123.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.3	97.6	(50.4-170.5)	Male	6	7.9	75.9	(27.7-165.2)
Female	2	3.6	nc	(nc-nc)	Female	6	5.5	109.1	(39.8-237.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
Female	45	44.0	102.3	(74.6-136.9)	Female	3	5.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	6.0	83.8	(27.0-195.6)
<u>Colon / Rectum</u>					Female	4	2.3	nc	(nc-nc)
Male	19	13.4	142.1	(85.5-221.9)	<u>Ovary</u>				
Female	16	10.7	149.1	(85.2-242.1)	Female	1	3.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.2	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	31	38.7	80.2	(54.5-113.8)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	11	8.7	127.1	(63.4-227.4)
Male	3	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.0	nc	(nc-nc)	Female	4	10.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.4	nc	(nc-nc)	Male	119	160.0	74.4	(61.6-89.0)
Female	2	1.3	nc	(nc-nc)	Female	139	143.6	96.8	(81.4-114.3)
<u>Lung and Bronchus</u>									
Male	10	22.0	45.5	(21.8-83.6)					
Female	17	18.9	89.8	(52.3-143.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	13.4	67.3	(30.7-127.8)	Male	12	8.7	137.3	(70.8-239.8)
Female	4	3.5	nc	(nc-nc)	Female	8	5.8	138.7	(59.7-273.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	40	48.7	82.1	(58.7-111.9)	Female	5	5.4	93.1	(30.0-217.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	9	6.7	133.4	(60.9-253.3)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	14	14.9	93.9	(51.3-157.6)	<u>Ovary</u>				
Female	9	11.1	80.9	(36.9-153.6)	Female	3	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	53	43.1	122.8	(92.0-160.7)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.3	nc	(nc-nc)
Male	6	7.8	77.2	(28.2-168.0)	Female	2	1.5	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.5	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	6	9.5	63.1	(23.1-137.4)
Male	4	5.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	3.1	194.1	(70.9-422.5)	Female	8	10.8	74.1	(31.9-146.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	4.9	nc	(nc-nc)	Male	149	176.9	84.2	(71.2-98.9)
Female	0	1.3	nc	(nc-nc)	Female	119	151.5	78.5	(65.1-94.0)
<u>Lung and Bronchus</u>									
Male	11	23.9	46.1	(23.0-82.5)					
Female	11	18.9	58.0	(28.9-103.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	55.3	101.3	(76.5-131.6)	Male	20	35.2	56.8	(34.7-87.8)
Female	19	22.2	85.7	(51.6-133.9)	Female	18	31.3	57.6	(34.1-91.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	10.9	128.5	(70.2-215.6)	Male	11	11.0	99.6	(49.6-178.1)
Female	11	9.8	112.6	(56.1-201.4)	Female	11	10.0	110.0	(54.9-196.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.9	nc	(nc-nc)	Male	29	31.6	91.7	(61.4-131.6)
Female	228	236.6	96.3	(84.2-109.7)	Female	27	31.1	86.9	(57.3-126.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.5	94.6	(40.7-186.5)	Male	28	24.8	112.7	(74.9-162.9)
<u>Colon / Rectum</u>					Female	14	12.9	108.8	(59.4-182.5)
Male	70	59.4	117.8	(91.8-148.8)	<u>Ovary</u>				
Female	75	64.5	116.3	(91.5-145.8)	Female	23	20.8	110.5	(70.1-165.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	13.6	102.9	(56.2-172.7)	Male	16	19.3	82.8	(47.3-134.5)
Female	7	4.3	164.3	(65.8-338.4)	Female	16	22.5	71.2	(40.7-115.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.0	119.2	(43.5-259.5)	Male	153	158.6	96.5	(81.8-113.0)
Female	5	4.5	111.3	(35.9-259.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	13.3	113.2	(63.3-186.7)
Male	27	29.6	91.2	(60.1-132.7)	Female	8	8.8	91.1	(39.2-179.4)
Female	25	19.1	130.9	(84.7-193.2)	<u>Testis</u>				
<u>Larynx</u>					Male	12	9.9	120.8	(62.4-211.0)
Male	9	7.9	114.2	(52.1-216.8)	<u>Thyroid</u>				
Female	3	2.6	nc	(nc-nc)	Male	11	14.3	76.8	(38.3-137.5)
<u>Leukemia</u>					Female	41	47.5	86.2	(61.9-117.0)
Male	28	22.6	124.2	(82.5-179.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	18.2	93.4	(54.4-149.6)	Female	54	52.8	102.2	(76.8-133.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	18.1	137.7	(89.1-203.4)	Male	715	697.2	102.6	(95.2-110.4)
Female	7	7.3	96.5	(38.7-198.8)	Female	828	816.6	101.4	(94.6-108.5)
<u>Lung and Bronchus</u>									
Male	114	96.3	118.4	(97.7-142.2)					
Female	134	114.2	117.4	(98.3-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	11.5	112.9	(60.1-193.1)	Male	9	7.9	113.5	(51.8-215.5)
Female	2	4.4	nc	(nc-nc)	Female	3	6.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.2	152.9	(76.2-273.7)
Female	58	54.5	106.5	(80.9-137.7)	Female	9	6.6	137.0	(62.5-260.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.8	nc	(nc-nc)
Male	17	13.7	124.2	(72.3-198.9)	<u>Ovary</u>				
Female	9	14.3	63.1	(28.8-119.9)	Female	5	4.6	107.5	(34.7-251.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.3	152.8	(49.2-356.5)	Male	3	4.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	54	41.7	129.6	(97.3-169.1)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	6	7.4	81.0	(29.6-176.4)	Female	0	1.9	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.5	104.5	(52.1-186.9)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	128.7	(41.5-300.3)	Female	12	11.8	101.5	(52.4-177.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	106.7	(34.4-249.1)	Male	175	163.4	107.1	(91.8-124.2)
Female	2	1.5	nc	(nc-nc)	Female	161	177.7	90.6	(77.2-105.7)
<u>Lung and Bronchus</u>									
Male	19	21.0	90.5	(54.5-141.4)					
Female	21	22.6	93.0	(57.5-142.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	30.0	50.0	(28.0-82.5)	Male	16	19.1	83.6	(47.8-135.8)
Female	9	11.2	80.2	(36.6-152.3)	Female	22	15.6	141.5	(88.6-214.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.8	86.2	(27.8-201.1)	Male	4	6.1	nc	(nc-nc)
Female	9	4.9	182.3	(83.2-346.2)	Female	3	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	23	17.2	133.6	(84.7-200.5)
Female	130	124.2	104.7	(87.4-124.3)	Female	19	15.8	120.4	(72.4-188.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.3	nc	(nc-nc)	Male	11	14.1	78.0	(38.9-139.6)
<u>Colon / Rectum</u>					Female	5	6.7	75.0	(24.2-175.1)
Male	45	32.5	138.5	(101.0-185.3)	<u>Ovary</u>				
Female	34	33.1	102.7	(71.1-143.6)	Female	7	10.7	65.3	(26.1-134.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	7.7	117.4	(53.6-222.9)	Male	16	10.6	150.5	(86.0-244.4)
Female	0	2.2	nc	(nc-nc)	Female	13	11.5	113.1	(60.2-193.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.2	nc	(nc-nc)	Male	83	92.8	89.4	(71.2-110.9)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.2	69.2	(22.3-161.5)
Male	13	16.8	77.2	(41.1-132.1)	Female	3	4.5	nc	(nc-nc)
Female	8	9.9	81.1	(34.9-159.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.3	nc	(nc-nc)
Male	7	4.4	158.9	(63.7-327.4)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	9	7.8	115.2	(52.6-218.8)
<u>Leukemia</u>					Female	26	23.2	111.9	(73.1-164.0)
Male	19	12.2	155.5	(93.6-242.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	9.2	109.1	(52.2-200.7)	Female	32	27.9	114.6	(78.3-161.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	10.2	48.9	(15.8-114.2)	Male	371	386.5	96.0	(86.5-106.3)
Female	5	3.7	135.6	(43.7-316.5)	Female	437	419.3	104.2	(94.7-114.5)
<u>Lung and Bronchus</u>									
Male	47	52.9	88.8	(65.3-118.1)					
Female	60	58.3	102.9	(78.5-132.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	6.1	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	17	24.2	70.2	(40.9-112.4)	Female	5	2.7	187.5	(60.4-437.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	3.3	150.5	(48.5-351.2)
<u>Colon / Rectum</u>					Female	0	1.2	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	<u>Ovary</u>				
Female	5	5.1	97.2	(31.3-226.9)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	21	22.0	95.6	(59.2-146.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.5	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.7	126.8	(46.3-275.9)
Male	5	2.6	195.3	(63.0-455.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.5	nc	(nc-nc)	Female	8	5.6	143.6	(61.9-283.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	62	84.7	73.2	(56.1-93.9)
Female	1	0.6	nc	(nc-nc)	Female	75	74.8	100.3	(78.9-125.7)
<u>Lung and Bronchus</u>									
Male	5	10.9	45.7	(14.7-106.6)					
Female	7	9.5	73.6	(29.5-151.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.0	85.3	(31.1-185.6)	Male	4	4.6	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	22	30.9	71.1	(44.6-107.7)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	9	7.8	116.1	(53.0-220.4)	<u>Ovary</u>				
Female	5	7.5	67.1	(21.6-156.6)	Female	5	2.6	190.5	(61.4-444.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	23	23.7	97.0	(61.4-145.5)
Female	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	1.7	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.9	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.7	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.0	nc	(nc-nc)	Female	1	7.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.6	nc	(nc-nc)	Male	90	94.1	95.6	(76.9-117.5)
Female	3	0.8	nc	(nc-nc)	Female	92	99.0	92.9	(74.9-113.9)
<u>Lung and Bronchus</u>									
Male	13	12.9	100.6	(53.5-172.1)					
Female	22	13.3	164.8	(103.3-249.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	45.8	93.8	(67.9-126.3)	Male	21	30.5	68.9	(42.6-105.3)
Female	22	18.3	120.1	(75.3-181.9)	Female	24	25.6	93.9	(60.2-139.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	9.8	123.0	(63.5-214.8)	Male	10	9.7	102.7	(49.2-188.9)
Female	11	8.2	134.1	(66.8-239.9)	Female	8	8.4	95.7	(41.2-188.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.6	nc	(nc-nc)	Male	34	27.4	124.2	(86.0-173.6)
Female	184	206.6	89.1	(76.7-102.9)	Female	25	25.8	96.7	(62.6-142.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.0	128.1	(58.5-243.2)	Male	22	23.6	93.3	(58.4-141.2)
<u>Colon / Rectum</u>					Female	8	10.9	73.7	(31.7-145.2)
Male	46	51.1	90.1	(66.0-120.2)	<u>Ovary</u>				
Female	54	53.5	100.9	(75.8-131.6)	Female	15	17.7	84.8	(47.4-139.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	12.4	72.8	(33.2-138.2)	Male	14	16.9	82.8	(45.2-138.9)
Female	3	3.6	nc	(nc-nc)	Female	22	18.5	118.6	(74.3-179.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.9	178.7	(71.6-368.2)	Male	149	154.7	96.3	(81.5-113.1)
Female	1	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	11.4	149.6	(87.1-239.5)
Male	30	27.4	109.7	(74.0-156.6)	Female	3	7.2	nc	(nc-nc)
Female	23	16.4	140.4	(88.9-210.6)	<u>Testis</u>				
<u>Larynx</u>					Male	13	7.1	183.9	(97.8-314.5)
Male	10	7.3	136.7	(65.4-251.3)	<u>Thyroid</u>				
Female	5	2.3	219.1	(70.6-511.2)	Male	16	12.8	125.1	(71.4-203.1)
<u>Leukemia</u>					Female	42	38.7	108.5	(78.2-146.7)
Male	27	19.5	138.4	(91.2-201.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	18	14.9	120.5	(71.4-190.4)	Female	46	45.9	100.3	(73.4-133.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	17.2	87.0	(48.7-143.6)	Male	639	622.3	102.7	(94.9-111.0)
Female	6	6.0	99.8	(36.4-217.2)	Female	721	691.2	104.3	(96.8-112.2)
<u>Lung and Bronchus</u>									
Male	101	83.5	120.9	(98.5-146.9)					
Female	128	97.1	131.8	(109.9-156.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	24.9	128.4	(87.8-181.2)	Male	19	16.2	117.0	(70.4-182.7)
Female	12	8.8	136.7	(70.5-238.7)	Female	9	12.7	70.7	(32.2-134.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	117.6	(42.9-256.0)	Male	5	5.3	95.2	(30.7-222.1)
Female	5	4.0	125.0	(40.3-291.7)	Female	6	4.1	147.2	(53.8-320.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	12	14.7	81.7	(42.2-142.8)
Female	115	104.3	110.3	(91.1-132.4)	Female	8	12.5	63.8	(27.5-125.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.5	172.1	(62.8-374.6)	Male	12	12.7	94.4	(48.7-165.0)
<u>Colon / Rectum</u>					Female	8	5.3	149.7	(64.5-295.0)
Male	33	27.8	118.8	(81.8-166.9)	<u>Ovary</u>				
Female	25	25.8	97.1	(62.8-143.3)	Female	11	8.9	124.3	(62.0-222.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.7	118.7	(51.1-233.9)	Male	13	9.1	142.8	(76.0-244.3)
Female	3	1.7	nc	(nc-nc)	Female	11	8.9	123.8	(61.7-221.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.9	nc	(nc-nc)	Male	90	86.5	104.0	(83.6-127.8)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.1	98.2	(35.8-213.7)
Male	21	14.9	140.7	(87.1-215.1)	Female	0	3.4	nc	(nc-nc)
Female	5	8.2	61.3	(19.8-143.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.4	148.3	(47.8-346.2)
Male	4	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	6	1.1	526.8	(192.3-1146.6)	Male	7	6.7	104.3	(41.8-214.9)
<u>Leukemia</u>					Female	24	19.5	122.9	(78.7-182.9)
Male	12	10.4	115.4	(59.6-201.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	7.2	181.6	(96.6-310.6)	Female	31	23.3	133.1	(90.4-189.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	9.1	143.0	(76.1-244.6)	Male	384	337.6	113.7	(102.6-125.7)
Female	7	2.9	238.9	(95.7-492.3)	Female	407	341.8	119.1	(107.8-131.2)
<u>Lung and Bronchus</u>									
Male	62	45.4	136.4	(104.6-174.9)					
Female	69	47.7	144.6	(112.5-183.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.7	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	13.2	68.3	(31.2-129.7)
Female	0	0.1	nc	(nc-nc)	Female	8	9.9	80.8	(34.8-159.3)
<u>Lung and Bronchus</u>									
Male	1	1.9	nc	(nc-nc)					
Female	2	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	10.7	139.6	(78.1-230.3)	Male	9	7.2	124.7	(56.9-236.8)
Female	2	2.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.3	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	6.5	214.1	(117.0-359.3)
Female	43	33.2	129.6	(93.8-174.6)	Female	7	4.0	175.6	(70.3-361.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	5.7	87.8	(28.3-204.9)
<u>Colon / Rectum</u>					Female	2	1.7	nc	(nc-nc)
Male	11	12.3	89.2	(44.5-159.7)	<u>Ovary</u>				
Female	11	8.1	136.3	(68.0-244.0)	Female	0	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	35	37.5	93.3	(65.0-129.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.7	nc	(nc-nc)
Male	2	6.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	5	2.6	191.2	(61.6-446.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	8	6.0	132.9	(57.2-261.8)
Male	5	4.5	110.0	(35.5-256.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.3	nc	(nc-nc)	Female	12	7.5	159.9	(82.5-279.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.0	nc	(nc-nc)	Male	156	148.1	105.4	(89.5-123.3)
Female	0	0.9	nc	(nc-nc)	Female	128	108.7	117.8	(98.3-140.1)
<u>Lung and Bronchus</u>									
Male	21	19.1	110.0	(68.0-168.1)					
Female	16	15.4	103.6	(59.2-168.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	26.3	170.9	(124.6-228.7)	Male	14	17.4	80.3	(43.9-134.7)
Female	14	9.7	144.0	(78.6-241.6)	Female	14	14.3	97.6	(53.3-163.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.5	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	5	4.6	108.2	(34.9-252.6)	Female	8	4.5	177.6	(76.5-349.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	23	15.7	146.4	(92.8-219.6)
Female	110	113.7	96.8	(79.5-116.6)	Female	21	14.1	149.4	(92.5-228.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.0	nc	(nc-nc)	Male	14	13.1	106.7	(58.3-179.0)
<u>Colon / Rectum</u>					Female	5	5.9	84.1	(27.1-196.3)
Male	31	29.7	104.3	(70.8-148.0)	<u>Ovary</u>				
Female	30	29.2	102.7	(69.3-146.6)	Female	9	9.8	92.3	(42.1-175.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	6.8	146.0	(69.9-268.6)	Male	8	9.5	83.8	(36.1-165.2)
Female	2	1.9	nc	(nc-nc)	Female	7	9.9	70.4	(28.2-145.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.3	218.4	(70.4-509.7)	Male	105	82.4	127.4	(104.2-154.3)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	14	6.5	215.3	(117.6-361.3)
Male	17	15.4	110.5	(64.3-176.9)	Female	1	4.0	nc	(nc-nc)
Female	13	8.9	146.7	(78.1-250.9)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.4	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
<u>Leukemia</u>					Female	23	22.4	102.8	(65.1-154.2)
Male	11	11.2	98.5	(49.1-176.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.3	133.0	(66.3-238.0)	Female	30	25.1	119.6	(80.7-170.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	9.4	63.7	(23.2-138.6)	Male	396	348.7	113.6	(102.7-125.3)
Female	3	3.2	nc	(nc-nc)	Female	404	377.7	107.0	(96.8-117.9)
<u>Lung and Bronchus</u>									
Male	47	46.5	101.1	(74.3-134.4)					
Female	60	50.9	117.9	(90.0-151.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	14.3	132.8	(79.9-207.5)	Male	6	9.5	63.3	(23.1-137.8)
Female	2	4.9	nc	(nc-nc)	Female	9	7.2	125.3	(57.2-238.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	6	3.0	196.8	(71.9-428.3)
Female	1	2.3	nc	(nc-nc)	Female	7	2.3	305.8	(122.5-630.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	17	8.6	198.8	(115.7-318.3)
Female	63	58.7	107.3	(82.5-137.3)	Female	3	7.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	10	7.4	135.2	(64.7-248.6)
<u>Colon / Rectum</u>					Female	3	3.0	nc	(nc-nc)
Male	10	15.9	62.9	(30.1-115.6)	<u>Ovary</u>				
Female	15	14.7	101.8	(56.9-167.9)	Female	5	5.0	100.6	(32.4-234.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.9	154.0	(56.2-335.3)	Male	6	5.3	113.4	(41.4-246.7)
Female	4	1.0	nc	(nc-nc)	Female	10	5.0	199.8	(95.7-367.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	54	49.5	109.1	(81.9-142.3)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	14	8.7	160.7	(87.8-269.7)	Female	3	2.0	nc	(nc-nc)
Female	6	4.6	130.5	(47.7-284.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	10	4.0	248.6	(119.0-457.2)
<u>Leukemia</u>					Female	13	11.2	116.3	(61.9-198.9)
Male	8	5.9	134.8	(58.0-265.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.1	145.9	(53.3-317.6)	Female	9	13.2	68.4	(31.2-129.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.1	117.0	(42.7-254.7)	Male	247	194.4	127.1	(111.7-144.0)
Female	1	1.7	nc	(nc-nc)	Female	208	192.7	108.0	(93.8-123.7)
<u>Lung and Bronchus</u>									
Male	46	26.2	175.5	(128.5-234.1)					
Female	31	26.2	118.1	(80.3-167.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	6.3	174.4	(86.9-312.1)	Male	3	4.7	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	32	35.0	91.4	(62.5-129.0)	Female	5	4.1	121.9	(39.3-284.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	6	4.1	147.7	(53.9-321.6)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	10	8.2	122.3	(58.5-224.9)	<u>Ovary</u>				
Female	10	8.5	117.8	(56.4-216.6)	Female	1	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	31	24.5	126.6	(86.0-179.7)
Female	3	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	6	4.5	132.1	(48.3-287.6)	Female	0	1.1	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	11	6.7	164.1	(81.8-293.7)
Male	4	2.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.4	211.4	(68.1-493.4)	Female	7	7.8	89.8	(36.0-185.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	106	96.1	110.2	(90.3-133.3)
Female	1	1.0	nc	(nc-nc)	Female	117	113.4	103.2	(85.4-123.7)
<u>Lung and Bronchus</u>									
Male	9	12.1	74.6	(34.1-141.7)					
Female	15	15.4	97.1	(54.3-160.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	2.1	242.6	(78.2-566.2)	Male	1	1.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	13	12.8	101.9	(54.2-174.3)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	3.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	12	7.9	151.0	(77.9-263.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.6	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.6	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.9	nc	(nc-nc)	Male	44	32.2	136.6	(99.2-183.3)
Female	1	0.3	nc	(nc-nc)	Female	37	41.0	90.3	(63.5-124.4)
<u>Lung and Bronchus</u>									
Male	7	3.9	179.3	(71.8-369.5)					
Female	11	5.3	207.2	(103.3-370.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	27.2	62.5	(36.4-100.1)	Male	34	17.1	199.2	(137.9-278.4)
Female	9	10.7	84.1	(38.4-159.7)	Female	24	14.2	168.8	(108.1-251.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.4	nc	(nc-nc)	Male	5	5.5	90.9	(29.3-212.0)
Female	5	4.7	105.5	(34.0-246.2)	Female	11	4.8	228.6	(114.0-409.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	17	15.5	109.6	(63.8-175.6)
Female	141	114.4	123.3	(103.7-145.4)	Female	11	14.8	74.3	(37.0-132.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.8	nc	(nc-nc)	Male	8	12.7	63.0	(27.1-124.1)
<u>Colon / Rectum</u>					Female	4	6.2	nc	(nc-nc)
Male	24	29.3	81.9	(52.5-121.9)	<u>Ovary</u>				
Female	28	31.5	89.0	(59.1-128.7)	Female	18	9.9	181.5	(107.5-286.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.9	130.3	(59.4-247.3)	Male	9	9.7	93.2	(42.5-176.9)
Female	4	2.1	nc	(nc-nc)	Female	11	11.0	100.4	(50.1-179.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.1	nc	(nc-nc)	Male	100	83.8	119.3	(97.0-145.1)
Female	5	1.9	269.0	(86.7-627.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.5	76.7	(24.7-179.1)
Male	12	14.9	80.3	(41.4-140.3)	Female	5	4.3	116.8	(37.6-272.6)
Female	12	9.2	130.7	(67.5-228.4)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.7	nc	(nc-nc)
Male	1	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	6.8	73.8	(23.8-172.2)
<u>Leukemia</u>					Female	34	20.9	162.5	(112.5-227.0)
Male	13	11.2	115.8	(61.6-198.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	8.7	91.9	(39.6-181.1)	Female	33	25.2	131.1	(90.2-184.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	9.3	53.8	(17.3-125.6)	Male	338	348.9	96.9	(86.8-107.8)
Female	1	3.4	nc	(nc-nc)	Female	445	390.6	113.9	(103.6-125.0)
<u>Lung and Bronchus</u>									
Male	34	47.8	71.2	(49.3-99.5)					
Female	48	55.2	87.0	(64.2-115.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.3	88.4	(42.3-162.6)	Male	5	7.1	69.9	(22.5-163.2)
Female	1	3.2	nc	(nc-nc)	Female	1	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	45	41.5	108.4	(79.0-145.0)	Female	7	4.8	144.7	(58.0-298.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	2	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.1	nc	(nc-nc)
Male	9	12.4	72.6	(33.1-137.8)	<u>Ovary</u>				
Female	5	9.5	52.7	(17.0-122.9)	Female	0	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	28	37.6	74.5	(49.5-107.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.7	nc	(nc-nc)
Male	5	6.4	77.8	(25.1-181.6)	Female	2	1.3	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.4	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	7	9.8	71.2	(28.5-146.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.1	nc	(nc-nc)	Male	106	148.1	71.6	(58.6-86.6)
Female	0	1.2	nc	(nc-nc)	Female	106	132.1	80.3	(65.7-97.1)
<u>Lung and Bronchus</u>									
Male	15	20.2	74.4	(41.6-122.7)					
Female	14	17.9	78.2	(42.7-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.1	79.6	(34.3-156.8)	Male	8	6.2	129.5	(55.8-255.2)
Female	6	3.9	152.5	(55.7-332.0)	Female	1	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.8	276.7	(89.2-645.8)	Male	3	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.5	90.3	(29.1-210.6)
Female	35	42.2	83.0	(57.8-115.4)	Female	3	5.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.4	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.3	nc	(nc-nc)
Male	9	10.5	85.4	(39.0-162.1)	<u>Ovary</u>				
Female	12	11.6	103.7	(53.5-181.1)	Female	8	3.7	217.6	(93.7-428.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.5	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	21	30.7	68.4	(42.3-104.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.4	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	7.3	nc	(nc-nc)
Male	7	4.0	176.6	(70.8-363.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.1	160.2	(51.6-373.8)	Female	12	9.8	122.9	(63.4-214.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.3	nc	(nc-nc)	Male	119	126.1	94.4	(78.2-112.9)
Female	0	1.3	nc	(nc-nc)	Female	125	143.5	87.1	(72.5-103.8)
<u>Lung and Bronchus</u>									
Male	18	17.5	102.8	(60.9-162.5)					
Female	17	20.1	84.5	(49.2-135.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	5	4.5	111.2	(35.9-259.6)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.6	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	20.7	53.2	(26.5-95.2)
Female	1	0.1	nc	(nc-nc)	Female	11	15.4	71.6	(35.7-128.1)
<u>Lung and Bronchus</u>									
Male	1	3.0	nc	(nc-nc)					
Female	1	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	4.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	4.1	194.7	(83.8-383.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	17	15.8	107.6	(62.6-172.2)
Female	0	0.1	nc	(nc-nc)	Female	7	14.8	47.4	(19.0-97.7)
<u>Lung and Bronchus</u>									
Male	0	2.1	nc	(nc-nc)					
Female	0	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.1	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.6	109.2	(35.2-254.7)	Male	8	2.8	290.0	(124.9-571.4)
Female	1	2.2	nc	(nc-nc)	Female	7	2.6	270.7	(108.4-557.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	17	20.8	81.7	(47.6-130.9)	Female	2	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	5	4.8	105.0	(33.8-245.0)	<u>Ovary</u>				
Female	6	6.3	95.6	(34.9-208.2)	Female	1	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	21	14.7	142.4	(88.1-217.7)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.1	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.2	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.6	nc	(nc-nc)	Female	5	4.8	105.2	(33.9-245.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.5	nc	(nc-nc)	Male	73	57.8	126.3	(99.0-158.8)
Female	1	0.7	nc	(nc-nc)	Female	64	73.3	87.3	(67.2-111.5)
<u>Lung and Bronchus</u>									
Male	10	8.0	125.0	(59.8-229.8)					
Female	6	10.8	55.6	(20.3-121.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	10.9	82.7	(37.7-157.0)	Male	18	7.3	246.9	(146.3-390.3)
Female	3	3.3	nc	(nc-nc)	Female	19	5.0	380.9	(229.2-594.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	8	2.3	341.4	(147.0-672.8)
Female	2	1.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
Female	52	40.3	128.9	(96.3-169.1)	Female	4	4.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	10	5.5	182.3	(87.3-335.3)
<u>Colon / Rectum</u>					Female	5	2.1	243.5	(78.5-568.3)
Male	7	12.0	58.3	(23.3-120.1)	<u>Ovary</u>				
Female	13	9.6	134.7	(71.7-230.4)	Female	3	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.9	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	4	0.7	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.0	nc	(nc-nc)	Male	33	35.6	92.6	(63.7-130.0)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.7	nc	(nc-nc)
Male	3	6.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.8	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Leukemia</u>					Female	13	8.1	161.4	(85.8-276.0)
Male	7	4.6	153.3	(61.4-315.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.8	nc	(nc-nc)	Female	11	9.1	121.5	(60.6-217.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.0	nc	(nc-nc)	Male	141	146.4	96.3	(81.1-113.6)
Female	0	1.1	nc	(nc-nc)	Female	168	131.9	127.4	(108.9-148.2)
<u>Lung and Bronchus</u>									
Male	15	19.8	75.8	(42.4-125.0)					
Female	20	18.1	110.7	(67.6-171.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	34.4	84.2	(56.4-120.9)	Male	17	22.6	75.3	(43.9-120.6)
Female	11	13.4	82.2	(41.0-147.0)	Female	18	18.9	95.1	(56.3-150.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.1	99.1	(39.7-204.3)	Male	3	7.2	nc	(nc-nc)
Female	8	6.1	131.6	(56.7-259.3)	Female	5	6.2	80.9	(26.1-188.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	16	20.3	78.9	(45.1-128.2)
Female	135	157.0	86.0	(72.1-101.8)	Female	13	19.0	68.4	(36.4-117.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	18	17.2	104.9	(62.1-165.8)
<u>Colon / Rectum</u>					Female	12	8.1	148.3	(76.5-259.1)
Male	38	38.1	99.8	(70.6-136.9)	<u>Ovary</u>				
Female	44	39.5	111.4	(80.9-149.5)	Female	19	13.3	143.0	(86.1-223.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	9.1	110.2	(52.7-202.6)	Male	10	12.5	80.0	(38.3-147.0)
Female	4	2.6	nc	(nc-nc)	Female	10	13.5	74.1	(35.5-136.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.8	nc	(nc-nc)	Male	110	110.9	99.2	(81.5-119.5)
Female	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	9	8.4	106.6	(48.7-202.4)
Male	20	20.1	99.7	(60.9-154.0)	Female	1	5.3	nc	(nc-nc)
Female	12	12.3	97.3	(50.2-169.9)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.1	136.5	(54.7-281.2)
Male	6	5.3	113.5	(41.4-247.0)	<u>Thyroid</u>				
Female	4	1.7	nc	(nc-nc)	Male	13	9.4	138.4	(73.6-236.6)
<u>Leukemia</u>					Female	28	28.8	97.1	(64.5-140.4)
Male	13	14.4	90.1	(47.9-154.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	11.0	45.6	(14.7-106.5)	Female	40	34.8	114.9	(82.1-156.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	12.4	56.5	(22.7-116.5)	Male	415	456.6	90.9	(82.4-100.1)
Female	3	4.5	nc	(nc-nc)	Female	462	516.0	89.5	(81.5-98.1)
<u>Lung and Bronchus</u>									
Male	47	61.6	76.3	(56.0-101.4)					
Female	55	72.1	76.3	(57.4-99.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	36.8	95.0	(66.2-132.2)	Male	30	22.1	135.6	(91.5-193.6)
Female	16	13.1	122.5	(70.0-199.0)	Female	18	17.0	106.0	(62.8-167.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.5	138.9	(63.4-263.8)	Male	8	7.1	113.0	(48.7-222.7)
Female	11	5.5	199.5	(99.4-357.0)	Female	4	5.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	27	20.0	135.1	(89.0-196.5)
Female	170	137.6	123.5	(105.7-143.6)	Female	24	17.9	134.2	(85.9-199.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.4	nc	(nc-nc)	Male	11	16.0	68.7	(34.2-122.9)
<u>Colon / Rectum</u>					Female	5	7.6	66.1	(21.3-154.3)
Male	29	38.7	74.9	(50.1-107.5)	<u>Ovary</u>				
Female	41	39.0	105.1	(75.4-142.6)	Female	11	11.9	92.1	(45.9-164.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	8.9	78.5	(31.5-161.8)	Male	9	12.8	70.2	(32.0-133.2)
Female	2	2.5	nc	(nc-nc)	Female	16	13.7	116.8	(66.7-189.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.2	nc	(nc-nc)	Male	115	106.0	108.5	(89.6-130.2)
Female	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	8.6	57.9	(18.7-135.1)
Male	17	18.8	90.5	(52.7-144.9)	Female	3	5.3	nc	(nc-nc)
Female	11	10.9	100.6	(50.1-180.0)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.5	nc	(nc-nc)
Male	2	5.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	8	8.0	100.1	(43.1-197.2)
<u>Leukemia</u>					Female	31	23.6	131.2	(89.1-186.3)
Male	10	14.5	68.8	(32.9-126.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	10.5	132.7	(72.5-222.7)	Female	31	30.5	101.7	(69.1-144.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	11.9	42.0	(13.5-97.9)	Male	404	449.5	89.9	(81.3-99.1)
Female	1	4.2	nc	(nc-nc)	Female	486	470.1	103.4	(94.4-113.0)
<u>Lung and Bronchus</u>									
Male	41	62.5	65.6	(47.1-89.1)					
Female	39	65.3	59.7	(42.5-81.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	102	94.8	107.5	(87.7-130.6)	Male	27	60.1	44.9	(29.6-65.4)
Female	31	38.4	80.7	(54.8-114.5)	Female	23	51.3	44.8	(28.4-67.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.8	85.3	(48.7-138.6)	Male	19	19.1	99.6	(59.9-155.5)
Female	13	16.7	77.9	(41.4-133.1)	Female	15	17.2	87.4	(48.9-144.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.3	nc	(nc-nc)	Male	44	54.1	81.3	(59.0-109.1)
Female	345	396.4	87.0	(78.1-96.7)	Female	49	52.7	93.0	(68.8-123.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	13.5	118.6	(67.8-192.7)	Male	55	43.9	125.3	(94.4-163.1)
<u>Colon / Rectum</u>					Female	27	21.9	123.4	(81.3-179.5)
Male	121	101.9	118.7	(98.5-141.9)	<u>Ovary</u>				
Female	105	112.8	93.1	(76.1-112.7)	Female	28	34.9	80.3	(53.4-116.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	28	23.9	116.9	(77.7-169.0)	Male	36	33.6	107.3	(75.1-148.5)
Female	9	7.3	122.8	(56.0-233.1)	Female	53	39.5	134.2	(100.5-175.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	7.7	104.4	(44.9-205.7)	Male	307	288.8	106.3	(94.7-118.9)
Female	5	6.8	73.8	(23.8-172.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	39	22.8	171.4	(121.9-234.3)
Male	56	52.0	107.8	(81.4-139.9)	Female	21	15.4	136.5	(84.4-208.6)
Female	35	32.2	108.8	(75.7-151.3)	<u>Testis</u>				
<u>Larynx</u>					Male	10	14.2	70.3	(33.7-129.3)
Male	27	13.8	195.1	(128.5-283.8)	<u>Thyroid</u>				
Female	8	4.5	179.1	(77.1-353.0)	Male	21	23.9	88.0	(54.4-134.5)
<u>Leukemia</u>					Female	77	74.8	102.9	(81.2-128.7)
Male	33	39.0	84.6	(58.2-118.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	20	31.6	63.4	(38.7-97.9)	Female	83	87.2	95.2	(75.8-118.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	65	32.2	202.0	(155.9-257.5)	Male	1370	1214.1	112.8	(106.9-119.0)
Female	13	12.2	106.3	(56.6-181.8)	Female	1297	1379.1	94.0	(89.0-99.3)
<u>Lung and Bronchus</u>									
Male	254	166.9	152.2	(134.0-172.1)					
Female	198	194.5	101.8	(88.1-117.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.2	143.9	(52.6-313.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	15.7	120.9	(72.8-188.8)
Female	0	0.1	nc	(nc-nc)	Female	13	15.2	85.4	(45.4-146.1)
<u>Lung and Bronchus</u>									
Male	1	2.0	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.8	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	10	9.0	111.4	(53.3-204.9)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.5	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	9.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	19	35.3	53.8	(32.4-84.0)
Female	0	0.3	nc	(nc-nc)	Female	24	29.6	81.2	(52.0-120.8)
<u>Lung and Bronchus</u>									
Male	1	5.0	nc	(nc-nc)					
Female	3	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.1	98.4	(31.7-229.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.3	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	18.6	80.7	(45.2-133.2)
Female	0	0.1	nc	(nc-nc)	Female	16	16.8	95.0	(54.3-154.3)
<u>Lung and Bronchus</u>									
Male	1	2.5	nc	(nc-nc)					
Female	1	2.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;